All In Biotech

NDA 020835 · Apil

Actonel

Risedronate Sodium · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Mar 27, 1998

Approved uses

12

Original approval plus efficacy supplements

Registered trials

95

42 Phase 3, 2 recruiting

FAERS reports

30,757

25,781 serious, 2,978 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 12, 2026.

Risedronate Sodium is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget’s disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate Sodium is indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Risedronate Sodium reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [ see Clinical Studies ( 14.1 , 14.2 ) ]. 1.2 Osteoporosis in Men Risedronate Sodium is indicated for treatment to increase bone mass in men with osteoporosis. 1.3 Glucocorticoid-Induced Osteoporosis Risedronate Sodium is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. 1.4 Paget’s Disease Risedronate Sodium is indicated for treatment of Paget’s disease of bone in men and women. 1.5 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of Risedronate Sodium for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy...

Mechanism: Risedronate Sodium has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, Risedronate Sodium inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that Risedronate Sodium treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • ACTONEL · RISEDRONATE SODIUM 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • ACTONEL · RISEDRONATE SODIUM 5MG · TABLET, ORAL · Discontinued · TE AB
  • ACTONEL · RISEDRONATE SODIUM 150MG · TABLET, ORAL · Prescription · TE AB
  • ACTONEL · RISEDRONATE SODIUM 35MG · TABLET, ORAL · Prescription · TE AB
  • ACTONEL · RISEDRONATE SODIUM 30MG · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Risedronate" as an intervention, any sponsor and status, largest first.

All 95 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • arthralgia3,863
  • pain3,826
  • drug ineffective3,764
  • dyspnoea3,107
  • nausea3,083
  • fatigue3,043
  • vomiting3,040
  • off label use2,973
  • diarrhoea2,773
  • drug hypersensitivity2,687
  • pneumonia2,667
  • malaise2,504

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,012
20051,174
20061,044
20071,141
20081,332
20091,656
20101,731
20111,455
20121,813
20131,177
2014902
20151,117
20161,124
2017898
2018930
20191,240
20201,521
20211,401
20221,647
20231,672
20241,911
20251,780
20261,078

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Actonel (Risedronate Sodium)

2024 spending

$970K

Beneficiaries

352

1,426 claims

Per beneficiary

$2,756

$171.25 per unit

View as table
YearSpending
2020$2,358,869
2021$1,788,278
2022$1,460,182
2023$1,132,973
2024$970,089

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 451 on PubMed

Sponsor: Apil

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.